
Supplemental figure 1. Forest plot of meta-analyzed associations of lipid-lowering drugs with prevalent AMD (model 1; RE=random-effects)

Models adjusted for study, age and sex Estimate [95% CI] EYERISK (n=6095) 23.15% 0.95 [0.83, 1.08] CES (n=948) 5.29% 0.67 [0.51, 0.89] GHS (n=7946) 13.24% 0.82 [0.69, 0.97] 15.43% 0.91 [0.77, 1.07] LIFE-Adult (n=4805) EPIC-Norfolk (n=5418) 15.49% 0.84 [0.72, 0.99] 12.82% 0.83 [0.70, 0.99] AugUR (n=2297) UEMS (n=3442) 3.70% 0.85 [0.61, 1.18] NICOLA (n=3265) 10.88% 0.80 [0.66, 0.97] RE Model 100.00% 0.86 [0.80, 0.91] 0.4 0.6 8.0 1.2 Odds ratio of lipid-lowering drugs use on any AMD


Supplemental figure 2. Forest plot of meta-analyzed associations of anti-diabetic drugs with prevalent AMD (model 1; RE=random-effects)

Models adjusted for study, age and sex Estimate [95% CI] EYERISK (n=7662) 16.22% 0.93 [0.77, 1.12] CES (n=948) 9.90% 0.60 [0.42, 0.88] GHS (n=7946) 14.74% 1.05 [0.84, 1.32] LIFE-Adult (n=4805) 16.09% 0.98 [0.81, 1.18] EPIC-Norfolk (n=5418) 9.74% 0.63 [0.43, 0.92] AugUR (n=2297) 14.57% 0.73 [0.58, 0.92] UEMS (n=4013) 9.62% 0.58 [0.40, 0.85] NICOLA (n=3265) 9.12% 0.68 [0.46, 1.02] RE Model 100.00% 0.79 [0.67, 0.93] 0.2 0.4 0.6 0.8 1 1.2 1.4 Odds ratio of antidiabetic drugs use on any AMD

Supplemental figure 3. Forest plot of meta-analyzed associations of lipid-lowering drugs with late AMD (model 2; RE=random-effects)



Supplemental figure 4. Forest plot of meta-analyzed associations of anti-diabetic drugs with late AMD (model 2; RE=random-effects)



Supplemental figure 5. Forest plot of meta-analyzed associations of NSAID with prevalent AMD (model 2; RE=random-effects)

Models adjusted for study, age,	sex, BMI, diabetes, hypertension, and smoking	Estimate [95% CI]
EYERISK (n=1408)	-	6.39% 1.05 [0.74, 1.49]
CES (n=911)	-	2.29% 0.91 [0.51, 1.64]
GHS (n=5218)	⊢■	23.54% 0.94 [0.78, 1.12]
LIFE-Adult (n=4529)	⊢ ■	26.05% 1.03 [0.87, 1.23]
EPIC-Norfolk (n=5418)	⊢	12.73% 0.94 [0.74, 1.21]
AugUR (n=2276)	⊢	11.68% 1.18 [0.91, 1.53]
UEMS (n=3649)	├	9.96% 1.01 [0.76, 1.33]
NICOLA (n=3241)	-	7.36% 1.16 [0.84, 1.61]
RE Model	-	100.00% 1.02 [0.93, 1.11]
	0.5 1 1.5 2	
	Odds ratio of NSAID use on any AMD	

Supplemental figure 6. Forest plot of meta-analyzed associations of NSAID with late AMD (model 2; RE=random-effects)

Models adjusted for study, age, sex, BMI, diabetes, hypertension, and smoking		Estimate [95% CI]
EYERISK (n=1408)	⊢■	39.86% 0.93 [0.63, 1.38]
GHS (n=5218)	-	18.79% 2.10 [1.03, 4.25]
AugUR (n=2276)	⊢■	30.38% 0.97 [0.59, 1.59]
UEMS (n=3649)	1	10.97% 1.33 [0.50, 3.56]
RE Model		100.00% 1.14 [0.80, 1.62]
	0 1 2 3 4 5	
	Odds ratio of NSAID use on late AMD	

Supplemental figure 7. Forest plot of meta-analyzed associations of anti-Parkinson drugs with prevalent AMD (model 2; RE=random-effects)

Models adjusted for study, age, sex, BMI, diabetes, hypertension, and smoking Estimate [95% CI] LIFE-Adult (n=4529) 23.68% 1.06 [0.49, 2.30] EPIC-Norfolk (n=5418) 11.91% 0.58 [0.19, 1.71] AugUR (n=2276) 48.16% 0.96 [0.56, 1.65] CES (n=911) 3.14% 0.22 [0.03, 1.83] NICOLA (n=3241) 13.11% 1.79 [0.63, 5.05] **RE Model** 100.00% 0.96 [0.66, 1.40] 2 Odds ratio of anti-Parkinson drugs use on any AMD

Supplemental figure 8. Forest plot of meta-analyzed associations of anti-Parkinson drugs with late AMD (model 2; FE= fixed effect)

